High-fidelity replication of the large RNA genome of coronaviruses (CoVs) is mediated by a 3'-to-5' exoribonuclease (ExoN) in non-structural protein 14 (nsp14), which excises nucleotides including antiviral drugs mis-incorporated by the low-fidelity viral RNA-dependent RNA polymerase (RdRp) and has also been implicated in viral RNA recombination and resistance to innate immunity. Here we determined a 1.6-Å resolution crystal structure of SARS-CoV-2 ExoN in complex with its essential co-factor, nsp10. The structure shows a highly basic and concave surface flanking the active site, comprising several Lys residues of nsp14 and the N-terminal amino group of nsp10. Modeling suggests that this basic patch binds to the template strand of double-stranded RNA substrates to position the 3' end of the nascent strand in the ExoN active site, which is corroborated by mutational and computational analyses. Molecular dynamics simulations further show remarkable flexibility of multi-domain nsp14 and suggest that nsp10 stabilizes ExoN for substrate RNA-binding to support its exoribonuclease activity. Our high-resolution structure of the SARS-CoV-2 ExoN-nsp10 complex serves as a platform for future development of anti-coronaviral drugs or strategies to attenuate the viral virulence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020977PMC
http://dx.doi.org/10.1101/2021.04.02.438274DOI Listing

Publication Analysis

Top Keywords

exoribonuclease exon
8
structure sars-cov-2
8
active site
8
exon
5
structure
4
structure dynamics
4
dynamics sars-cov-2
4
sars-cov-2 proofreading
4
proofreading exoribonuclease
4
exon high-fidelity
4

Similar Publications

Article Synopsis
  • The development of antiviral drugs for SARS-CoV-2 is essential due to limited treatment options and the possibility of reinfection after vaccination.
  • Two key viral targets for drug development are the 3'-5' exoribonuclease (ExoN) and the 2'-O-methyltransferase (2'-O-MTase), which are crucial for the virus's survival.
  • The study utilizes target-directed dynamic combinatorial chemistry (tdDCC) to find compounds that inhibit the interactions of essential viral proteins, resulting in a new class of inhibitors that show antiviral activity against coronaviruses.
View Article and Find Full Text PDF

During RNA turnover, the action of endo- and exo-ribonucleases can yield RNA decay intermediates with specific 5' ends. These RNA decay intermediates have been demonstrated to be the outcome of decapping, microRNA-directed endo-cleavage, or the protected fragments of ribosomes and exon-junction complexes. Therefore, global analysis of RNA decay intermediates can facilitate studies of many RNA decay pathways.

View Article and Find Full Text PDF
Article Synopsis
  • Coronaviruses encode 16 nonstructural proteins that form replication-transcription complexes crucial for viral RNA synthesis, with nsp14 acting as a key exoribonuclease for proofreading and replication fidelity.
  • Mutations introduced at the nsp14-nsp10 interface in murine hepatitis virus led to varying levels of impairments in replication and exonuclease activity, highlighting the importance of this interaction.
  • The study's findings emphasize the potential of targeting the nsp14-10 interface for developing viral inhibitors and improving understanding of coronavirus pathogenesis.
View Article and Find Full Text PDF

Utilization of the EpiMed Coronabank Chemical Collection to identify potential SARS-CoV-2 antivirals: in silico studies targeting the nsp14 ExoN domain and PL naphthalene binding site.

J Mol Graph Model

September 2024

Epigenomic Medicine Laboratory at prospED Polytechnic, Carlton, VIC, 3053, Australia; Epigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, 75 Commercial Road, Prahran, VIC, 3004, Australia; Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC, 3010, Australia; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia. Electronic address:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome encodes 29 proteins including four structural, 16 nonstructural (nsps), and nine accessory proteins (https://epimedlab.org/sars-cov-2-proteome/). Many of these proteins contain potential targetable sites for the development of antivirals.

View Article and Find Full Text PDF

New insights into complex formation by SARS-CoV-2 nsp10 and nsp14.

Nucleosides Nucleotides Nucleic Acids

November 2024

Department of Biology & Lund Protein Production Platform & Protein Production Sweden, Lund University, Lund, Sweden.

Article Synopsis
  • SARS-CoV-2 non-structural protein 10 (nsp10) is crucial for activating the enzymatic functions of nsp14 and nsp16, helping the virus improve its resistance to antiviral drugs and evade the immune system.
  • Nsp14 has dual functions, including proofreading viral RNA and adding a protective cap, while nsp10 facilitates these activities through specific binding with varying truncations affecting its functionality.
  • Research utilized advanced techniques to reveal that the full structure of nsp10 enhances its interaction with nsp14, demonstrating complex dynamics not fully observable by traditional methods like X-ray crystallography.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!